Guiding the starting dose of the once-daily formulation of tacrolimus in “de novo” adult renal transplant patients: a population approach
The 36% between-patient variability in CL/F was explained by CYP3A5 genotype, age, and hematocrit. Hematocrit standardization to 45% explained the variability of tacrolimus whole-blood concentrations, and this was of utmost importance in order to better interpret whole-blood tacrolimus concentrations during therapeutic drug monitoring. The dose requirements of CYP3A5<i>*/1</i> carriers in patients aged 60 years or younger would be highest, while CYP3A5<i>*/1</i> non-carriers older than 60 years would require the lowest doses.
Authors
- Anna Vidal‐Alabró (ORCID: https://orcid.org/0000-0001-7695-2372)
- Helena Colom (ORCID: https://orcid.org/0000-0002-7259-0199)
- Núria Montero (ORCID: https://orcid.org/0000-0002-5123-4603)
- Edoardo Melilli (ORCID: https://orcid.org/0000-0001-6965-3745)
- Anna Manonelles (ORCID: https://orcid.org/0000-0003-2456-388X)
- Beatriz Fernández-Alarcón
- Raül Rigo‐Bonnin (ORCID: https://orcid.org/0000-0001-5511-074X)
- Josep M. Grinyó (ORCID: https://orcid.org/0000-0002-7435-3808)
- Ana Coloma (ORCID: https://orcid.org/0000-0002-1773-9560)
- Núria Lloberas (ORCID: https://orcid.org/0000-0002-3387-5757)
- Sergi Codina (ORCID: https://orcid.org/0000-0002-2313-6109)
- Oscar Nolberger
- Àlex Favà
- Josep María Cruzado
Institutions
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-19
- DOI
- https://doi.org/10.3389/fphar.2024.1456565
- Citations
- 2
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.02
Funders
- Centres de Recerca de Catalunya
- Generalitat de Catalunya
- Instituto de Salud Carlos III
- European Regional Development Fund